SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock, SD Anker, J Butler… - The Lancet, 2020 - thelancet.com
Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
被引用次数：1171 相关文章

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock, SD Anker, J Butler… - The Lancet, 2020 - Elsevier
Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock… - Lancet (London …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing
empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition …

[引用][C] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock, SD Anker, J Butler… - The Lancet, 2020 - cir.nii.ac.jp
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis
of the EMPEROR-Reduced and DAPA-HF trials | CiNii Research CiNii 国立情報学研究所 学術 …

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

F Zannad, JP Ferreira, SJ Pocock, SD Anker… - Lancet (London …, 2020 - europepmc.org
Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing
empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition …

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock, SD Anker, J Butler… - The Lancet, 2020 - hal.science
Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing
empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition …
[PDF] smcmaroc.org

[PDF][PDF] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock, SD Anker, J Butler… - 2020 - smcmaroc.org
Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
[PDF] hal.science

[PDF][PDF] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock, SD Anker, J Butler… - 2020 - hal.science
Evidence before this study: Large cardiovascular outcome trials in patients with type 38 2
diabetes (T2D) have demonstrated that sodium-glucose cotransporter 2 inhibitors 39 …
[PDF] smcmaroc.org

[PDF][PDF] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

F Zannad, JP Ferreira, SJ Pocock, SD Anker, J Butler… - 2020 - smcmaroc.org
Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …